Soufflé Therapeutics emerged from stealth with a $200 million Series A to develop cell‑specific siRNA therapeutics, the company announced. The financing and founding team include figures tied to Moderna and Bob Langer; the startup plans to advance genetic medicines that are designed to be cell‑selective and to partner with Big Pharma on development and commercialization. Soufflé’s strategy aims to combine targeted RNA modalities with delivery and cell‑specificity to broaden the therapeutic index of siRNA programs. The large series A underscores investor appetite for RNA platforms that promise improved targeting and tolerability beyond systemic drugs.